EMA Authorised: Kefdensis (denosumab) — Stada Arzneimittel AG

View source ↗

Summary

Authorised status for Kefdensis (denosumab) by Stada Arzneimittel AG for bone resorption disorders including osteoporosis and postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Resorption Disorders
• Osteoporosis
• Osteoporosis Postmenopausal

Drugs mentioned

• Kefdensis (denosumab)

Snippet

Status: Authorised. Therapeutic area: Bone Resorption;Osteoporosis;Osteoporosis, Postmenopausal. MAH: Stada Arzneimittel AG. Decision date: 16/06/2026